Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
Overview:
The Phase 1b trial of Viking Therapeutics’ VK0214 for X-linked adrenoleukodystrophy (X-ALD) showed that VK0214 was safe and well-tolerated over a 28-day period. Patients treated with VK0214 demonstrated significant reductions in very long-chain fatty acids (VLCFAs) and plasma lipid levels, including LDL cholesterol and apolipoprotein B. These findings suggest potential benefits for managing X-ALD’s biomarkers. Further clinical steps are planned to explore VK0214’s efficacy.
For more details, you can view the original report here.
*The United Leukodystrophy Foundation is not liable for any inaccuracies or gaps in these overviews , which are offered “as is” without assurances on completeness, accuracy, or timeliness. For verification or detailed information, please consult the original articles directly.
As a leukodystrophy related nonprofit, the ULF provides awareness to scientific literature. Inclusion on our website does not imply endorsement of, or agreement with, the contents by the ULF.